Aerie pharmaceuticals to announce second quarter 2018 financial results and host conference call on wednesday, august 8, 2018

Durham, n.c.--(business wire)--aerie pharmaceuticals, inc. (nasdaq:aeri) (aerie or the company), announced today that its second quarter 2018 financial results will be released after the market closes on wednesday, august 8, 2018. following the release, the company will host a live conference call and webcast at 5:00 p.m. eastern time to discuss the company’s financial results and provide a general business update. the live webcast and a replay may be accessed by visiting the company's website at http://investors.aeriepharma.com. please connect to the company's website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. alternatively, please call (888) 734-0328 (u.s.) or (678) 894-3054 (international) to listen to the live conference call. the conference id number for the live call 1773437. please dial in approximately 10 minutes prior to the call. telephone replay will be available approximately two hours after the call. to access the replay, please call (855) 859-2056 (u.s.) or (404) 537-3406 (international). the conference id number for the replay is 1773437. the telephone replay will be available until august 15, 2018. about aerie pharmaceuticals, inc. aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye. aerie's first product, rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eyedrop approved by the u.s. food and drug administration (fda) for the reduction of elevated intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension, was launched in the united states in april 2018. in clinical trials of rhopressa®, the most common adverse reactions were conjunctival hyperemia, cornea verticillata, instillation site pain, and conjunctival hemorrhage. more information about rhopressa®, including the product label, is available at www.rhopressa.com. aerie’s advanced-stage product candidate, roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, a fixed-dose combination of rhopressa® and the widely-prescribed pga (prostaglandin analog) latanoprost, achieved its 3-month primary efficacy endpoint in two phase 3 registration trials, mercury 1 and mercury 2, and also showed safety and efficacy throughout 12 months in mercury 1. aerie submitted the roclatan™ new drug application (nda) in may 2018 and, in july 2018, the fda set the pdufa (prescription drug user fee act) goal date for the completion of the fda’s review of the roclatan™ nda for march 14, 2019. aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema. more information is available at www.aeriepharma.com.
AERI Ratings Summary
AERI Quant Ranking